Literature DB >> 6811413

Selective effects of Adriamycin on murine host defense systems.

M J Ehrke, S A Cohen, E Mihich.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6811413     DOI： 10.1111/j.1600-065x.1982.tb00427.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN： 0105-2896            Impact factor:   12.988


× No keyword cloud information.
  14 in total

1.  Enhancement of interleukin-2 release in rats by treatment with bleomycin and adriamycin in vivo.

Authors:  T A Abdul Hamied; J L Turk
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.

Authors:  R C Bocian; S Ben-Efraim; S Dray; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

3.  Indomethacin modulation of adriamycin-induced effects on multiple cytolytic effector functions.

Authors:  D L Maccubbin; S A Cohen; M J Ehrke
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Enhanced expansion of the thymic CD8+ cell subset as a potential mechanism for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers.

Authors:  M M Bartik; B A Baumgartel-Scofield; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.

Authors:  L M Weiskirch; E Barker; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  Effect of anticancer drugs on the release of interleukin-6 in vitro.

Authors:  S I Hasan; B A Blaney; J L Turk
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

7.  Adriamycin induced resistance of sensitive K 562 cells to natural killer lymphocyte attack.

Authors:  H Benoist; C Madoulet; J C Jardillier; A Desplaces
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

8.  Adriamycin-induced activation of NK activity may initially involve LAF production.

Authors:  S A Cohen; D Salazar; J Wicher
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

9.  Systemic activation of macrophages by liposome-entrapped muramyl tripeptide in mice pretreated with the chemotherapeutic agent adriamycin.

Authors:  G Hisano; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

10.  Cytolytic T lymphocytes and antibodies to myocytes in adriamycin-treated BALB/c mice. Evidence for immunity to drug-induced antigens.

Authors:  S A Huber; A Moraska
Journal:  Am J Pathol       Date:  1992-01       Impact factor: 4.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.